|
TFDP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
5.94099991424457E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
8.242400E-01 |
| Stage1-vs-Stage3 |
3.096200E-02 |
| Stage1-vs-Stage4 |
2.915600E-03 |
| Stage2-vs-Stage3 |
1.247970E-01 |
| Stage2-vs-Stage4 |
2.372000E-02 |
| Stage3-vs-Stage4 |
2.369000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.73270000003445E-06 |
| Normal-vs-Asian |
1.63113966777928E-12 |
| Caucasian-vs-AfricanAmerican |
3.444200E-01 |
| Caucasian-vs-Asian |
3.971200E-01 |
| AfricanAmerican-vs-Asian |
7.968800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.961600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
1.37879999639878E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.020400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.323900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.813200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.178800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.978200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.817000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.360000E-03 |
| Classical-VS-Follicular |
6.874000E-02 |
| Classical-VS-Other |
7.444000E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
3.186200E-04 |
| Tall-VS-Other |
5.116000E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
4.204800E-01 |
| Follicular-VS-Normal |
1.11569642413656E-11 |
| Other-VS-Normal |
1.83529999997489E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62436730732907E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
8.278200E-02 |
|
|
